Digital Cognitive Behavioral Therapy (dCBT-I) for Maternal Insomnia

Digital Cognitive Behavioral Therapy (dCBT-I) for Maternal Insomnia During Pregnancy

Insomnia symptoms are common during pregnancy, especially in the second and third trimesters, which can reach more than 68%. Insomnia during pregnancy is not only associated with increased risk of preeclampsia, gestational diabetes, preterm labor, and cesarean section, but also increased postpartum poor sleep and postpartum depression. Cognitive behavioral therapy (CBT-I) and drug therapy for insomnia are the two main methods of insomnia treatment. Drug therapy is the more commonly used traditional treatment method, but there may be certain drug risks. Therefore, non-drug methods for Insomnia in pregnant women is much safer.

Cognitive-behavioral therapy for insomnia is a psychological therapy for insomnia. Compared with sedative-hypnotic drugs, its therapeutic effect is slow, but the curative effect is long-lasting, with less relapse after treatment and no invasive side effects. Multiple guidelines recommend it as first-line therapy for insomnia. And "Digital Cognitive Behavioral Therapy" (dCBT-I), is based on CBT-I, a therapy provided by the Internet and smartphones, which simulates face-to-face CBT-I in reality. It can provide more convenient medical services for the special group of pregnant women, improve sleep, improve mental symptoms, life treatment, and reduce the risk of adverse outcomes for mothers and children.

The Womens' Hospital, Zhejiang University School of Medicine is conducting a clinical study on "Digital Cognitive Behavioral Therapy (dCBT-I) for maternal Insomnia during pregnancy". The primary goal of this research project was to examine the efficacy of dCBT-I ("RuMian") in the treatment of maternal insomnia. "RuMian" is a fully automatic dCBT-I application developed in China, and subjects will use it for free.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 36 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Age 18-40 years old
  • 20-32 weeks of pregnancy, singleton pregnancy and regular obstetric examination at Zhejiang University Women's Hospital
  • There has been a high frequency of insomnia symptoms
  • According to the preliminary assessment by the project team, it meets the diagnostic criteria for insomnia
  • Possess a smart phone and can operate it proficiently, with normal reading and writing comprehension ability, clear consciousness, and able to cooperate with the research to complete the questionnaire independently.

Exclusion Criteria:

  • Assess the risk of preterm birth and concurrent pregnancy-related diseases;
  • Completion of the 7-day sleep diary in the baseline period < 4 days;
  • Combined with severe anxiety/depression;
  • Suicidal tendencies or severe mental illness (bipolar disorder, schizophrenia, paranoid psychosis, etc.);
  • Edinburgh Pregnancy Depression Scale (EPDS) total score ≥ 15;
  • Have drug dependence or have taken anti-anxiety, anti-depression, sedative or hypnotic drugs for mental diseases within the past 3 months;
  • Participated in interventions such as meditation courses, childbirth yoga or cognitive behavioral therapy in the past 1 year;
  • Complicated with serious physical diseases such as heart failure and tumor;
  • Combined with sleep disorders such as severe obstructive sleep apnea that require further evaluation and treatment;
  • There is alcohol and cigarette dependence;
  • Shift work;
  • Severe visual or hearing impairment and unable to use mobile phones normally;
  • Physical illness with unstable condition, or illness itself that may interfere with cognitive behavioral therapy for insomnia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: dCBT-I treatment group
  1. Complete the evaluation of various scales and record a 7-day sleep diary before entering the group
  2. Receive a 6-week treatment after enrollment, insist on using the app every day (about 5-10 minutes), and receive regular follow-up from the project doctor
  3. Scale assessment needs to be completed at the end of treatment
  4. One month after the end of treatment, cooperate with relevant follow-up and complete the scale evaluation
Other Names:
  • Device: smartphone

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of "Insomnia Severity Index(ISI)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
Insomnia Severity Index(ISI),the minimum and maximum values are 0 and 28, and higher scores mean a worse outcome.
From before treatment to the end of treatment (an average of 42 days)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of "Pittsburgh Sleep Quality Index(PSQI)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
Pittsburgh Sleep Quality Index(PSQI),the minimum and maximum values are 0 and 21, and higher scores mean a worse outcome.
From before treatment to the end of treatment (an average of 42 days)
Change of "sleep onset latency(SOL)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
simple questionnaire will be used to assess this outcome of sleep onset latency(SOL)
From before treatment to the end of treatment (an average of 42 days)
Change of "wake up after sleep onset(WASO)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
simple questionnaire will be used to assess this outcome of WASO
From before treatment to the end of treatment (an average of 42 days)
Change of "sleep efficiency(SE)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
combination of questionnaire and calculate will be used to assess this outcome of SE
From before treatment to the end of treatment (an average of 42 days)
Change of "Number of wake ups during the night"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
Number of wake ups during the night
From before treatment to the end of treatment (an average of 42 days)
Change of "total sleep time(TST)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
total sleep time(TST)
From before treatment to the end of treatment (an average of 42 days)
Change of "Edinburgh Pregnancy Depression Scale(EPDS)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
Edinburgh Pregnancy Depression Scale(EPDS),the minimum and maximum values are 0 and 30, and higher scores mean a worse outcome.
From before treatment to the end of treatment (an average of 42 days)
Change of "Self-rating Anxiety Scale(SAS)"
Time Frame: From before treatment to the end of treatment (an average of 42 days)
Self-rating Anxiety Scale(SAS), the minimum and maximum values are 25 and 100, and higher scores mean a worse outcome.
From before treatment to the end of treatment (an average of 42 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

June 1, 2022

Primary Completion (Anticipated)

July 15, 2022

Study Completion (Anticipated)

June 1, 2023

Study Registration Dates

First Submitted

May 16, 2022

First Submitted That Met QC Criteria

May 24, 2022

First Posted (Actual)

May 27, 2022

Study Record Updates

Last Update Posted (Actual)

May 27, 2022

Last Update Submitted That Met QC Criteria

May 24, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)

Clinical Trials on dCBT-I

Subscribe